Background
==========

Soft tissue sarcomas (STS) constitute a highly heterogeneous collection of tumors comprising over 50 histological subtypes, arising from mesenchymal tissue and capable of forming tumors in all parts of the human body \[[@B1]\]. This group amounts to 0.5-1% of the annual tumor burden with a mortality of about 40-60%, resulting in an estimated 11 280 cases and 3 900 deaths in the US in 2012 \[[@B2]\]. It is good practice to distinguish between STSs arising in the extremity & trunk (ET), head & neck (HN) and visceral & retroperitoneal (VR) localizations as treatment and prognosis vary widely according to localization \[[@B3]\]. Further subdivision, according to histological type, malignancy grade, stage and vascular invasion among others, can be conducted \[[@B3]\]. Definitive treatment is radical surgery followed by radiotherapy in case of non-radical surgical margins \[[@B4]\]. Adjuvant chemotherapy for adult STS is still under investigation, and hence the routine use of such treatment is today limited to the palliative setting \[[@B5]\].

Angiogenesis is the process of forming new blood vessels from pre-existing ones. Folkman and coworkers proved this to be a pivotal step in carcinogenesis by showing that tumors would not grow beyond \> 2 mm in diameter without forming vasculature \[[@B6],[@B7]\]. In 2001, Hanahan and Weinberg, suggested angiogenesis as one of the hallmarks of cancer \[[@B8]\] and in the 2011 updated version angiogenesis was still considered one of the most important aspects of cancer progression \[[@B9]\].

Vascular endothelial growth factors (VEGF) and receptors (VEGFR) are pivotal in endothelial cell proliferation and sprouting during angio- and lymphangiogenesis \[[@B10]\]. Platelet-derived growth factors (PDGF) and receptors (PDGFR) play an important part in the regulation of tumor stroma through the recruitment of pericytes and vascular smooth muscle cells helping to stabilize newly formed vessels and through stimulation of stromal cells to produce VEGF-A and thus drive angiogenesis \[[@B11],[@B12]\]. Fibroblast growth factors (FGF) and receptors (FGFR) drives endothelial cell proliferation and sprouting and activate several molecules involved in extracellular matrix remodelling including matrix metallo-proteinases and urokinase-like plasminogen activator \[[@B13]\].

Our group has previously reported on the expression of VEGF, PDGF and FGF families of growth factors in STSs of all sites \[[@B14]-[@B16]\]. This report investigates the differential impact of these growth factors in STSs arising in ET versus VR localizations.

Methods
=======

Patients and clinical samples
-----------------------------

Primary tumor tissue from anonymized patients diagnosed with STS at the University Hospital of North-Norway and the Hospitals of Arkhangelsk County, Russia, from 1973 through 2006, were collected. In total 496 patients were registered from the hospital databases. Of these, 388 patients were excluded from the study because of: missing clinical data (n = 86), inadequate formalin-fixed paraffin-embedded (FFPE) tissue blocks (n = 161), no surgery performed and/or metastasis present at the time of diagnosis (n = 55) or head and neck sarcomas (n =13). Thus 115 patients with STSs of the extremities and trunk wall and 66 patients with STSs of visceral or retroperitoneal origin, with complete medical records and FFPE tissue blocks were eligible.

This report includes follow-up data as of September 2009. The median follow-up was 53.9 (range 0.5-391.7) months for extremity and trunk patients and 59.4 (range 0.10-366.7) months for visceral and retroperitoneal patients. Complete demographic and clinical data were collected retrospectively. Formalin-fixed and paraffin-embedded tumor specimens were obtained from the archives of the Departments of Pathology at the University Hospital of North-Norway and the Hospitals of Arkhangelsk County, Russia. The tumors were graded according to the French Fédération Nationale des centres de Lutte Contre le Cancer (FNCLCC) system and histologically subtyped according to the World Health Organization guidelines \[[@B1],[@B17]\]. Wide resection margins were defined as wide local resection with free microscopic margins or amputation of the affected limb or organ.

Microarray construction
-----------------------

All sarcomas were histologically reviewed by two trained pathologists (S. Sorbye and A. Valkov) and the most representative areas of tumor cells (neoplastic mesenchymal cells) were carefully selected and marked on the hematoxylin and eosin (H/E) slide and sampled for the tissue microarray (TMA) blocks. The TMAs were assembled using a tissue-arraying instrument (Beecher Instruments, Silver Springs, MD). The Detailed methodology has been previously reported \[[@B18]\]. Briefly, we used a 0.6 mm diameter stylet, and the study specimens were routinely sampled with four replicate core samples from different areas of neoplastic tissue. Normal tissue from the patients was used as staining control.

To include all core samples, 12 TMA blocks were constructed. Multiple 5-μm sections were cut with a Micron microtome (HM355S) and stained by specific antibodies for immunohistochemistry (IHC) analysis.

Immunohistochemistry
--------------------

The applied antibodies were subjected to in-house validation by the manufacturer for IHC analysis on paraffin-embedded material. The detailed methodology has previously been reported \[[@B14]-[@B16]\].

Scoring of immunohistochemistry
-------------------------------

The ARIOL imaging system (Genetix, San Jose, CA) was used to scan the slides of antibody staining of the TMAs and the dominant staining intensity was scored as: 0 = negative; 1 = weak; 2 = intermediate; 3 = strong semi-qantitively on computer screen. The detailed methodology has previously been reported and cut-off values chosen were the same as in our previous studies \[[@B14]-[@B16]\]. High expression in tumor cells were defined as ≥ 1 (VEGF-C), ≥ 1.5 (PDGF-A, PDGF-C, PDGF-B, VEGF-A, VEGF-D, VEGFR-1-2 and -3) and ≥ 2 (PDGF-D, PDGFR-α, PDGFR-β, FGF2 and FGFR-1).

Statistical methods
-------------------

All statistical analyses were done using the statistical package SPSS (Chicago, IL), version 16. The IHC scores from each observer were compared for interobserver reliability by use of a two-way random effect model with absolute agreement definition. The intraclass correlation coefficient (reliability coefficient) was obtained from these results. The Chi-square test and Fishers Exact test were used to examine the association between molecular marker expression and various clinicopathological parameters. Univariate analyses were done using the Kaplan-Meier method, and statistical significance between survival curves was assessed by the log-rank test. Disease-specific survival (DSS) was determined from the date of diagnosis to the time of cancer related death. Metastasis-free survival (MFS) was defined from the date of diagnosis to the clinical appearance of the first metastasis. Recurrence-free survival (RFS), was defined from the date of diagnosis to the clinical appearance of the first recurrence. To assess the independent value of different pretreatment variables on survival, metastasis and local recurrence, in the presence of other variables, multivariate analyses were carried out using the Cox proportional hazards model. Only variables of significant value from the univariate analyses were entered into the Cox regression analysis. Probability for stepwise entry and removal was set at .05 and .10, respectively. The significance level used for all statistical tests was P \< 0.05.

Ethical clearance
-----------------

The Norwegian National Data Inspection Board and The Regional Committee for Research Ethics (Northern Norway) approved the study.

Results
=======

Clinicopathological variables
-----------------------------

The clinicopathological variables are summarized in Table [1](#T1){ref-type="table"}. In the ET group, comprising 115 patients, median age was 59 (range 0-89) years, 50% of the patients were male, 67 patients were Norwegian and 48 Russian and 68% of the tumors were located in the extremities. Of the histological subtypes represented, 48 were undifferentiated pleomorphic sarcomas, 18 liposarcomas, 12 fibrosarcomas, 10 synovial sarcomas, 9 leiomyosarcomas, 5 angiosarcomas, 5 rhabdomyosarcomas, 5 malignant peripheral nerve sheath tumors (MPNST) and 3 sarcoma not otherwise specified (NOS).

###### 

Prognostic clinicopathological variables as predictors for disease-specific survival, metastasis and local recurrence in patients with resected Extremitiy & Trunk and Visceral & Retroperitoneal soft-tissue sarcomas (univariate analyses, log rank test, n = 115 and 66 respectively)

                            **Extremity & trunk**   **Visceral & retroperitoneal**                                                                                     
  ------------------------- ----------------------- -------------------------------- --------- ----- --------- ---- --------- ---- ----- --------- ----- ------- ----- ---------
  **Age**                                                                                                                                                               
  ≤ 20 years                12                      42                               0.431     42    0.129     73   0.690     1    0     \<0.001   100   0.112   100   0.786
  21-60 years               48                      61                                         63              69             36   71              67            71     
  \> 60 years               55                      55                                         69              64             29   43              44            62     
  **Gender**                                                                                                                                                            
  Male                      57                      56                               0.298     66    0.368     66   0.759     15   79    0.039     86    0.022   66    0.799
  Female                    58                      54                                         61              67             51   51              48            68     
  **Patient nationality**                                                                                                                                               
  Norwegian                 67                      65                               0.004     74    0.008     71   0.249     54   62    0.051     59    0.122   66    0.892
  Russian                   48                      42                                         48              57             12   36              46            59     
  **Histological entity**                                                                                                                                               
  Pleomorphic sarcoma       48                      42                               0.004     61    0.001     56   0.664     6    50    0.917     67    0.264   40    0.274
  Leiomyosarcoma            9                       100                                        78              78             39   55              46            77     
  Liposarcoma               18                      83                                         94              89             13   62              81            54     
  Fibrosarcoma              12                      57                                         67              55             0                                         
  Angiosarcoma              5                       40                                         20              67             2    50              50            50     
  Rhabdomyosarcoma          5                       60                                         60              60             1                    100           100    
  MPNST                     5                       53                                         60              60             4    67              100           100    
  Synovial sarcoma          10                      13                                         30              64             1    100             0             0      
  Sarcoma NOS               3                       100                                        67              67             0                                         
  **Tumor size**                                                                                                                                                        
  \< 5 cm                   38                      70                               0.048     81    0.053     74   0.085     11   82    0.107     73    0.259   89    0.006
  5-10 cm                   45                      48                                         53              61             24   62              62            70     
  \> 10 cm                  30                      49                                         58              62             31   45              45            49     
  Missing                   2                                                                                                                                           
  **Malignancy grade**                                                                                                                                                  
  1                         29                      89                               \<0.001   89    0.001     85   0.054     23   78    0.005     77    0.051   86    0.046
  2                         41                      56                                         65              60             29   46              42            58     
  3                         45                      35                                         43              57             14   46              47            49     
  **Vascular invasion**                                                                                                                                                 
  Absent                    64                      70                               \<0.001   85    \<0.001   79   \<0.001   43   59    0.656     60    0.847   66    0.675
  Present                   50                      35                                         33              43             20   51              54            78     
  Missing                   1                                                                                                 3                                         
  **Tumor depth**                                                                                                                                                       
  Superficial               12                      91                               0.010     100   0.012     91   0.041     32                                        
  Deep                      103                     51                                         59              63             34                                        
  **Resection margins**                                                                                                                                                 
  Wide                      61                      66                               0.004     72    0.045     82   \<0.001   50   65    0.021     59    0.654   90    \<0.001
  Non-wide                  54                      44                                         54              46             16   50              53            44     

*Abbreviations*: *MPNST* Malingnant peripheral nerve sheat tumor, *NOS* Not otherwise specified.

In the VR group, median age was 58 (range 13-88) years, 23% of the patients were male and 54 patients were Norwegian and 12 Russian. Of the histological subtypes represented, 39 were leiomyosarcomas, 13 liposarcomas, 6 pleomorphic sarcomas, 4 neurofibrosarcomas/MPNSTs, 2 angiosarcomas, 1 rhabdomyosarcoma and 1 synovial sarcoma.

Interobserver variability
-------------------------

Interobserver scoring agreement was tested for PDGF-B, PDGFR-α, VEGF-C, VEGFR-3, FGF2 and FGFR1 and found to be good (0.77-0.90, P \< 0.001) \[[@B14]-[@B16]\].

Univariate analyses
-------------------

The impact of the clinicopathological variables on DSS, MFS and RFS in the ET group are summarized in Table [1](#T1){ref-type="table"}. Patient nationality (P = 0.004), histological entity (p = 0.004), tumor size (p = 0.048), malignancy grade (P \< 0.001), vascular invasion (P \<0.001), tumor depth (P = 0.010) and resection margins (P = 0.004) were all prognostic indicators of DSS. Patient nationality (P = 0.008), histological entity (P = 0.001), malignancy grade (P = 0.001), vascular invasion (P \< 0.001), tumor depth (P = 0.012) and resection margins (P = 0.045) were prognostic indicators of MFS. Finally, vascular invasion (P \< 0.001), tumor depth (P = 0.041) and resection margins (P \< 0.001) were prognostic indicators of RFS.

The impact of the angiogenic markers on DSS, MFS and RFS in the ET group are summarized in Table [2](#T2){ref-type="table"}. PDGF-A (P = 0.035), PDGF-B (P = 0.006), PDGF-C (P = 0.032), PDGF-D (P = 0.003), PDGFR-α (P = 0.002), PDGFR-β (P = 0.029), VEGF-A (P = 0.001), VEGFR-1 (P = 0.001) and FGF2 (P = 0.033) were prognostic indicators of DSS. PDGF-A (P = 0.007), PDGF-B (P = 0.003), PDGFR-α (P = 0.002), PDGFR-β (P = 0.002), VEGF-A (P = 0.001), VEGFR-1 (P \< 0.001) and VEGFR-3 (P = 0.008) were prognostic indicators of MFS. PDGF-A (P = 0.012), PDGF-B (P = 0.015), PDGFR-α (P = 0.011), VEGF-A (P = 0.002) and VEGFR-1 (P = 0.036) were prognostic indicators of RFS.

###### 

Angiogenic markers as predictors for disease-specific survival, metastasis and local recurrence in patients with resected soft-tissue sarcomas of the extremities or trunk (univariate analyses, log rank test, n = 115)

                     **Disase-specific survival**   **Metastasis-free survival**   **Recurrence-free survival**                  
  ------------- ---- ------------------------------ ------------------------------ ------------------------------ --------- ---- -------
  **PDGF-A**                                                                                                                      
  Low           54   60                             0.035                          74                             0.007     79   0.012
  High          58   52                                                            51                                       55    
  Missing       3                                                                                                                 
  **PDGF-B**                                                                                                                      
  Low           44   68                             0.006                          78                             0.003     82   0.015
  High          68   48                                                            52                                       56    
  Missing       3                                                                                                                 
  **PDGF-C**                                                                                                                      
  Low           31   71                             0.032                          68                             0.214     68   0.564
  High          80   50                                                            61                                       65    
  Missing       4                                                                                                                 
  **PDGF-D**                                                                                                                      
  Low           73   67                             0.003                          70                             0.051     77   0.002
  High          40   34                                                            49                                       42    
  Missing       2                                                                                                                 
  **PDGFR-α**                                                                                                                     
  Low           69   67                             0.002                          74                             0.002     77   0.011
  High          43   38                                                            42                                       45    
  Missing       3                                                                                                                 
  **PDGFR-β**                                                                                                                     
  Low           85   64                             0.029                          72                             0.002     69   0.825
  High          24   32                                                            35                                       58    
  Missing       6                                                                                                                 
  **VEGF-A**                                                                                                                      
  Low           60   65                             0.001                          75                             0.001     77   0.002
  High          51   43                                                            48                                       51    
  Missing       4                                                                                                                 
  **VEGF-C**                                                                                                                      
  Low           69   55                             0.476                          68                             0.083     68   0.232
  High          38   60                                                            56                                       63    
  Missing       8                                                                                                                 
  **VEGF-D**                                                                                                                      
  Low           84   57                             0.131                          67                             0.081     70   0.177
  High          29   50                                                            51                                       55    
  Missing       2                                                                                                                 
  **VEGFR-1**                                                                                                                     
  Low           67   63                             0.002                          77                             \<0.001   72   0.036
  High          44   46                                                            43                                       58    
  Missing       4                                                                                                                 
  **VEGFR-2**                                                                                                                     
  Low           78   58                             0.332                          67                             0.189     71   0.240
  High          28   52                                                            53                                       57    
  Missing       9                                                                                                                 
  **VEGFR-3**                                                                                                                     
  Low           75   60                             0.053                          70                             0.008     70   0.159
  High          34   45                                                            46                                       57    
  Missing       6                                                                                                                 
  **FGF2**                                                                                                                        
  Low           75   61                             0.033                          66                             0.214     70   0.648
  High          35   49                                                            56                                       67    
  Missing       6                                                                                                                 
  **FGFR-1**                                                                                                                      
  Low           83   58                             0.460                          64                             0.411     66   0.768
  High          26   47                                                            55                                       71    
  Missing       6                                                                                                                 

*Abbreviations*: *PDGF* Platelet-derived growth factor, *PDGFR* Platelet-derived growth factor receptor, *VEGF* Vascular endothelial growth factor, *VEGFR* Vascular endothelial growth factor receptor, *FGF* Fibroblast growth factor, *FGFR* Fibroblast growth factor receptor.

The impact of the clinicopathological variables on DSS, MFS and RFS in the VR group are summarized in Table [1](#T1){ref-type="table"}. Age (P \< 0.001), gender (P = 0.039), malignancy grade (P = 0.005) and resection margins (P = 0.021) were prognostic indicators of DSS. Gender (P = 0.022) was a prognostic indicator of MFS and tumor size (P = 0.006), malignancy grade (P = 0.046) and resection margins (P \< 0.001) were prognostic indicators of RFS.

The impact of angiogenic markers on DSS, MFS and RFS in the VR group is summarized in Table [3](#T3){ref-type="table"}. FGRF-1 (P = 0.023) was the only prognostic indicator for DSS and PDGF-C (P = 0.045) for RFS.

###### 

Angiogenic markers as predictors for disease-specific survival, metastasis and local recurrence in patients with resected visceral & retroperitoneal soft-tissue sarcomas (univariate analyses, log rank test, n = 66)

                     **Disase-specific survival**   **Metastasis-free survival**   **Recurrence-free survival**                
  ------------- ---- ------------------------------ ------------------------------ ------------------------------ ------- ---- -------
  **PDGF-A**                                                                                                                    
  Low           23   49                             0.473                          63                             0.593   65   0.315
  High          39   63                                                            54                                     73    
  Missing       4                                                                                                               
  **PDGF-B**                                                                                                                    
  Low           14   54                             0.604                          82                             0.088   61   0.291
  High          48   59                                                            51                                     73    
  Missing       4                                                                                                               
  **PDGF-C**                                                                                                                    
  Low           20   39                             0.297                          59                             0.986   53   0.045
  High          41   65                                                            56                                     76    
  Missing       5                                                                                                               
  **PDGF-D**                                                                                                                    
  Low           48   52                             0.078                          52                             0.197   70   0.343
  High          15   80                                                            73                                     59    
  Missing       3                                                                                                               
  **PDGFR-α**                                                                                                                   
  Low           41   56                             0.672                          61                             0.527   71   0.761
  High          21   61                                                            51                                     66    
  Missing       4                                                                                                               
  **PDGFR-β**                                                                                                                   
  Low           58   57                             0.360                          54                             0.532   70   0.766
  High          4    75                                                            75                                     75    
  Missing       4                                                                                                               
  **VEGF-A**                                                                                                                    
  Low           34   51                             0.326                          64                             0.719   64   0.054
  High          29   68                                                            53                                     79    
  Missing       3                                                                                                               
  **VEGF-C**                                                                                                                    
  Low           34   66                             0.402                          69                             0.071   62   0.051
  High          29   50                                                            45                                     84    
  Missing       3                                                                                                               
  **VEGF-D**                                                                                                                    
  Low           34   60                             0.856                          62                             0.388   63   0.116
  High          30   55                                                            51                                     78    
  Missing       2                                                                                                               
  **VEGFR-1**                                                                                                                   
  Low           37   55                             0.724                          63                             0.358   70   0.510
  High          25   63                                                            49                                     71    
  Missing       3                                                                                                               
  **VEGFR-2**                                                                                                                   
  Low           44   55                             0.858                          63                             0.446   69   0.821
  High          19   67                                                            48                                     75    
  Missing       3                                                                                                               
  **VEGFR-3**                                                                                                                   
  Low           36   54                             0.552                          59                             0.821   65   0.220
  High          25   61                                                            52                                     76    
  Missing       5                                                                                                               
  **FGF2**                                                                                                                      
  Low           39   56                             0.805                          51                             0.214   74   0.748
  High          20   65                                                            67                                     66    
  Missing       7                                                                                                               
  **FGFR-1**                                                                                                                    
  Low           43   45                             0.023                          56                             0.385   68   0.448
  High          20   89                                                            63                                     78    
  Missing       3                                                                                                               

*Abbreviations*: *PDGF* Platelet-derived growth factor, *PDGFR* Platelet-derived growth factor receptor, *VEGF* Vascular endothelial growth factor, *VEGFR* Vascular endothelial growth factor receptor, *FGF* Fibroblast growth factor, *FGFR* Fibroblast growth factor receptor.

Multivariate cox proportional hazards analysis
----------------------------------------------

Table [4](#T4){ref-type="table"} presents multivariate analyses of clinicopathological and angiogenic marker variables with respect to DSS, MFS and RFS in the ET and VR groups, respectively.

###### 

Multivariate analyses of clinopathological variables and angiogenic markers as prognostic values for disease-specific survival, metastasis and local recurrence in patients with resected soft-tissue sarcomas of the trunk or extremities (cox proportional hazards test)

                                   **Disase-specific survival**                  **Metastasis-free survival**           **Recurrence-free survival**                                       
  -------------------------------- ------------------------------ -------------- ------------------------------ ------- ------------------------------ --------- --------- --------------- ---------
  **Extremity & trunk**                                                                                                                                                                    
  **Malignancy grade**                                                                                                                                                                      
  1                                1.000                                         \<0.001\*                                                                                                  
  2                                4.066                          1.389-11.901   0.010                                                                                                      
  3                                6.025                          2.058-17.634   0.001                                                                                                      
  **Vascular invasion**                                                                                                                                                                     
  Absent                           1.000                                                                        1.000                                            1.000                      
  Present                          2.141                          1.188-3.859    0.011                          5.284   2.418-11.544                   \<0.001   2.135     1.019-4.475     0.045
  **Resection margins**                                                                                                                                                                     
  Wide                             1.000                                                                                                                         1.000                      
  Non-wide                         1.818                          1.032-3.203    0.039                                                                           2.687     1.289-5.602     0.008
  **PDGF-B**                                                                                                                                                                                
  Low                                                                                                                                                            *1.000*                    
  High                                                                                                                                                           *2.099*   *0.937-4.706*   *0.072*
  **PDGF-D**                                                                                                                                                                                
  Low                              1.000                                                                                                                         *1.000*                    
  High                             1.863                          1.057-3.283    0.031                                                                           *1.844*   *0.931-3.653*   *0.079*
  **VEGF-A**                                                                                                                                                                                
  Low                                                                                                                                                            1.000                      
  High                                                                                                                                                           2.095     1.028-4.271     0.042
  **VEGFR-1**                                                                                                                                                                               
  Low                                                                                                           1.000                                                                       
  High                                                                                                          2.106   1.038-4.272                    0.039                                
  **Visceral & retroperitoneal**                                                                                                                                                           
                                                                                                                                                                                            
  **Gender**                                                                                                                                                                                
  Male                                                                                                          1.000                                                                       
  Female                                                                                                        4.612   1.089-19.536                   0.038                                
  **Malignancy grade**                                                                                                                                                                      
  1                                1.000                                         0.003\*                                                                         1.000                     0.061
  2                                4.812                          1.823-12.705   0.002                                                                           2.069     0.630-6.794     0.231
  3                                5.646                          1.790-17.804   0.003                                                                           5.665     1.330-24.123    0.019
  **Resection margins**                                                                                                                                                                     
  Wide                             1.000                                                                                                                         1.000                      
  Non-wide                         2.712                          1.222-6.018    0.014                                                                           11.996    3.128-46.005    \<0.001
  **PDGF-C**                                                                                                                                                                                
  Low                                                                                                                                                            *1.000*                    
  High                                                                                                                                                           *0.413*   *0.157-1.089*   *0.074*
  **FGFR-1**                                                                                                                                                                                
  Low                              1.000                                                                                                                                                    
  High                             0.243                          0.095-0.618    0.003                                                                                                      

*Abbreviations*: *HR* Hazard ratio, *CI* Confidence interval, *VEGF* Vascular endothelial growth factor, *VEGFR* Vascular endothelial growth factor receptor, *PDGFR* Platelet-derived growth factor receptor, *FGFR* Fibroblast growth factor receptor, \*overall significance as prognostic factor.

In the ET group, high malignancy grade (P \< 0.001), the presence of vascular invasion (P = 0.011), non-wide resection margins (P = 0.039) and high expression of PDGF-D (HR = 1.863, 95% CI = 1.057-3.283, P = 0.031) were significant independent prognostic indicators of DSS. Further, the presence of vascular invasion (P \< 0.001) and high expression of VEGFR-1 (HR = 2.106, 95% CI = 1.038-4.272, P = 0.039) were significant independent prognostic factors of MFS, while the presence of vascular invasion (P = 0.045), non-wide resection margins (P = 0.008) and high expression of VEGF-A (HR 2.095, 95% CI 1.028-4.271, P = 0.042) were significant independent prognostic factors of RFS.

In the VR group, high malignancy grade (P = 0.003) and non-wide resection margins (P = 0.014) were significant independent adverse prognostic indicators of DSS whereas high FGFR-1 expression (HR = 0.243, 95% CI = 0.095-0.618, P = 0.003) was an independent positive prognostic indicator of DSS. Female gender (P = 0.038) was an independent negative prognostic indicator of MFS while non-wide resection margins (P \< 0.001) was an independent negative prognostic indicator of RFS.

Discussion and conclusions
==========================

In our univariate analyses high expression of most examined angiogenic markers were prognosticators of DSS and/or MFS and/or RFS in the ET group. Further, PDGF-D was an independent negative prognostic indicator of DSS, VEGFR-1 an independent negative prognostic indicator of MFS and VEGF-A an independent negative prognostic indicator of RFS. In contrast, only FGFR-1 was a prognosticator of DSS in both the univariate and multivariate analyses of the VR group. To our knowledge, this is the first comparison of the expression of angiogenic molecules in ET versus VR STSs.

Current knowledge of the importance of tumor localization (ET versusVR tumors) when it comes to the prognostic impact of angiogenic markers in STSs is limited. Yudoh et. al. investigated the level of VEGF-A in tissue from ET patients and found high levels to predict survival, local recurrence and metastasis \[[@B18]\]. We have previously reported on the expression of PDGFs, VEGFs and FGFs in a larger cohort of STS of mixed sites and histology and found high expression of VEGFR-3, PDGF-B and FGF2 to have independent negative prognostic impact on DSS \[[@B14]-[@B16]\]. When comparing the expression of angiogenic markers based on tumor location, it becomes apparent that these variables almost exclusively have prognostic impact in STS arising in the ET group (Tables [2](#T2){ref-type="table"}, [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}). This difference could to some extent be due to a smaller number of patients in the VR group, with a resulting increased risk of false negative results. However, near all angiogenic markers showed significant prognostic impact in the univariate analyses of the ET group, whereas only FGFR-1 showed prognostic impact in the VR group. Table [1](#T1){ref-type="table"} summarizes the clinopathological values in the ET and VR groups and it is apparent that the VR group contains a higher percentage of leiomysarcomas and liposarcomas. The different distribution of histologies between the ET and VR groups might suggest that angiogenic markers have higher impact in STSs arising in ET locations. Another explanation may be that ET tumors, even the slow growing ones, will produce symptoms when they reach a certain size due to limits created by connective and muscle tissue and blood and lymph vessels. VR tumors could in contrast grow to significant size before producing symptoms. This may explain our results as VR tumors in many cases only are found after the angiogenic switch have occurred, thus the impact of angiogenic markers have been negated in these tumors.

In the PDGF-axis, all markers were prognosticators of DSS, all but PDGF-C were prognosticators of MFS and all but PDGF-C and PDGFR-β were prognosticators of RFS in the ET group (Table [2](#T2){ref-type="table"}), while none of the PDGFs were prognosticators in the VR group. Further, PDGF-D was found to be an independent negative prognostic factor for DSS in the ET group. In our previous study, PDGF-B was an independent prognosticator of DSS \[[@B15]\], and in this study PDGF-D is an independent prognosticator of DSS. PDGF-B binds all PDGFRs while PDGF-D binds PDGFR-αβ and-ββ \[[@B11]\]. Both PDGF-B and PDGF-D has been shown to exhibit similar and extensive angiogenic and transforming abilities \[[@B19],[@B20]\]. Although our results cannot distinguish whether PDGF signalling drives tumor development through angiogenesis or other pathways, they strongly suggest PDGF signalling to be an important part of STS growth and progression.

In the VEGF-axis, VEGF-A, and VEGFR-1 were prognosticators of DSS, MFS and RFS in the ET group, while none of the VEGFs were prognosticators in the VR group (Table [2](#T2){ref-type="table"}). Further, VEGFR-1 was an independent prognostic indicator of MFS and VEGF-A was an independent prognostic indicator of RFS in the ET group. VEGF-A signalling is the major angiogenic pathway, and high tumor expression and availability in serum has previously been associated with malignancy grade, metastasis, local recurrence and worse overall survival in STS patients \[[@B18],[@B21]-[@B26]\]. VEGFR-1 is thought to modulate VEGF-A signalling through VEGFR-2, has anti-angiogenic properties in its soluble form, and has been linked to metastasis in experimental studies suggesting a feasible biological link for our finding in these STS patients \[[@B27],[@B28]\]. This latter finding is quite interesting as antibodies and small-molecules targeting VEGFR-1 are being developed \[[@B29],[@B30]\].

In the FGF-axis, FGF-2 was an unfavorable prognostic indicator of DSS in ET group. FGF2 is thought to drive cell-cycling, activate extracellular matrix remodelling and to rescue PDGF-B and VEGF-A driven angiogenesis in the presence of their respective inhibitors \[[@B13],[@B31],[@B32]\]. Surprisingly, FGFR-1 was an independent positive indicator of DSS in the VR group. To our knowledge these are new data, but these results have to be validated before a firm conclusion may be drawn due to the low number of patients.

This study enhances our current knowledge on angiogenic prognosticators in STSs, strongly indicates the involvement of the PDGF and VEGF pathways in ET STS development and adds to the growing body of evidence suggesting that STSs of different sites and histology should be analyzed independently in future studies. Further emphasis should also be put on validating VEGFR-1 as a predictor of MFS in ET STS patients, as these patients may benefit from adjuvant therapy targeting VEGFR-1.
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